List of SBIR/STTR awards granted to Progenics Pharmaceuticals
Progenics PharmaceuticalsA SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $366,535.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $100,000.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $3,029,040.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $2,640,409.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $3,036,480.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $550,179.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $2,707,682.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $196,950.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $614,996.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $594,489.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $600,638.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $3,830,890.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $520,839.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $351,433.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $620,713.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $291,281.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $617,186.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $591,376.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $428,780.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $3,635,260.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals from the U.S. Department of Health & Human Services.
A SBIR Phase II contract was awarded to Progenics Pharmaceuticals for $473,537.0 USD from the U.S. Department of Health & Human Services.
A SBIR Phase I contract was awarded to Progenics Pharmaceuticals for $371,046.0 USD from the U.S. Department of Health & Human Services.
